Obesity Drugs: Lower Prices, Better Access for Retirees

White House Announces Deal to Lower Prices of Anti-Obesity Drugs for Medicare RecipientsThe White House has struck a deal with Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity drugs, Zepbound and Wegovy. This agreement aims to make these medications more accessible, particularly for older American women on Medicare, who often face unique health and financial challenges. Starting next year, co-payments for eligible Medicare patients will be no more than fifty dollars a month, significantly lowering the cost of these life-changing drugs. This move is expected to improve medical health and boost the financial well-being of many retirees, potentially saving taxpayers money by reducing costs associated with obesity-related conditions. DNN | The Daily News Now! The world’s first global local news network. Every city. Every story. AI powered. Hosted on Acast. See acast.com/privacy for more information.